Table: Santen Pharm -Q1 group results (IFRS)
06/08/2021 07:00
Aug 6 (Reuters)-
Santen Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Jun 30, 2021 Jun 30, 2020 Mar 31, 2022
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 64.99 57.56 260.00
(+12.9 pct) (-2.7 pct) (+4.2 pct)
Operating 9.54 8.02 41.50
(+19.0 pct) (-13.3 pct) (+221.3 pct)
Pretax 9.55 8.36 41.00
(+14.3 pct) (-7.1 pct) (+230.2 pct)
Net 7.38 6.19
(+19.3 pct) (-3.3 pct)
EPS Basic 18.47 yen 15.49 yen 77.07 yen
EPS Diluted 18.44 yen 15.46 yen
Ann Div 28.00 yen 32.00 yen
-Q2 Div 14.00 yen 16.00 yen
-Q4 Div 14.00 yen 16.00 yen
NOTE - Santen Pharmaceutical Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T